Pulse Biosciences, Inc (NASDAQ:PLSE) major shareholder Robert W. Duggan bought 409,918 shares of the company’s stock in a transaction on Monday, September 18th. The stock was bought at an average cost of $14.36 per share, for a total transaction of $5,886,422.48. Following the completion of the transaction, the insider now directly owns 3,437,994 shares of the company’s stock, valued at $49,369,593.84. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) opened at 16.13 on Thursday. Pulse Biosciences, Inc has a 12 month low of $5.20 and a 12 month high of $39.50. The firm has a 50-day moving average price of $20.35 and a 200 day moving average price of $25.32. The firm’s market capitalization is $231.21 million.
Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Thursday, July 27th. The company reported ($0.43) EPS for the quarter.
COPYRIGHT VIOLATION NOTICE: This story was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/21/robert-w-duggan-acquires-409918-shares-of-pulse-biosciences-inc-plse-stock.html.
Hedge funds have recently made changes to their positions in the stock. Nationwide Fund Advisors acquired a new stake in Pulse Biosciences in the 2nd quarter valued at $177,000. The Manufacturers Life Insurance Company acquired a new stake in Pulse Biosciences in the 2nd quarter valued at $250,000. California Public Employees Retirement System acquired a new stake in Pulse Biosciences in the 2nd quarter valued at $297,000. OxFORD Asset Management LLP acquired a new stake in Pulse Biosciences in the 2nd quarter valued at $310,000. Finally, Rhumbline Advisers acquired a new stake in Pulse Biosciences in the 2nd quarter valued at $325,000. 9.56% of the stock is currently owned by institutional investors and hedge funds.
About Pulse Biosciences
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Receive News & Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.